AstraZeneca has signed an agreement with French biotech company Transgene to develop cancer drug candidates using genetically engineered vaccinia viruses.
3 May 2019 News
2 May 2019 Comment
NDC is far from being a breakthrough therapy in ovarian cancer, but it has the potential to augment the treatment regimens indicated for ovarian cancer.
1 May 2019 Comment
R2-CHOP failed to meet its primary endpoint of demonstrating superiority in progression-free survival (PFS) compared to R-CHOP.
30 April 2019 News
University of Cambridge spin out PolyProx Therapeutics has announced it has raised £3.4m of seed capital, led by Cambridge Innovation Capital (CIC), RT Capital and Cambridge Enterprise.
29 April 2019 Analysis
The top ten orphan drugs in oncology accounted for approximately $54.1bn in net sales in 2018, with just three of Roche’s drugs Herceptin, Avastin and Rituxan collectively accounting for approximately...
29 April 2019 News
AstraZeneca and MSD have received a positive opinion for Lynparza (olaparib) as a first-line maintenance treatment of BRCA-mutated advanced ovarian cancer.
24 April 2019 News
China-headquartered antibody engineering company Adagene and Swiss oncology-focused ADC Therapeutics have announced they have entered into a drug discovery collaboration and license agreement.
23 April 2019 pressreleases
Creative Pharma Services attended the Hellenic Society for Pharmaceutical Management on 18 April.
23 April 2019 projects
The University of Southampton’s Centre of Cancer Immunology is situated at Southampton General Hospital.